1. Home
  2. Community
  3. Promotions
  4. Accelerating CAR-T Cell Therapy Research for the Fight against Cancer

There is no question that using a patient’s own immune system to fight cancer is one of the major medical breakthroughs of the 21st century.

--- Dr. Ran Reshef (the Clinical Lead for the CAR-T Cell Program at Columbia)

Chimeric antigen receptor (CAR) T-cell therapy represents an immunotherapeutic approach that enhances the immune system's ability to detect and eliminate cancer cells. The intricate nature of the human immune system encompasses diverse cell populations and intricate signaling networks distributed throughout the body. Within this context, lymphocytes, a subset of white blood cells, play a crucial role in combating infections. Specifically, T cells, a type of lymphocyte, exhibit the capacity to recognize and eliminate cancer cells as well as virally infected cells. Harnessing the potential of T cells in CAR T-cell therapy, researchers aim to bolster their tumor-targeting capabilities. By doing so, CAR T-cell therapy holds promise in enabling T cells to overcome the evasive mechanisms employed by cancer cells, facilitating their selective destruction.

CAR T-cell therapy has emerged as a viable treatment option for various malignancies, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL) in the pediatric and young adult population up to the age of 25. Notably, the U.S. Food and Drug Administration (FDA) has granted approval to five CAR T-cell therapies as of March 2021.

The landscape of CAR T-cell therapy research extends beyond its current applications, encompassing investigations into the utilization of existing FDA-approved products for novel indications and in populations with limited treatment options. Concurrently, efforts are underway to enhance the safety profile of CAR T-cell therapy, thereby mitigating potential adverse events associated with its administration. The ongoing advancements in CAR T-cell therapy research evoke a sense of optimism within the cancer community, fostering anticipation for its future prospects and the transformative impact it holds for individuals affected by cancer.

Cyagen based on its years of research experience in the field of tumor immunotherapy can provide CAR-T and other cell therapy researchers with services and comprehensive support for the research and development of CAR-T and other cell therapies.

This session is ideal for researchers, scientists, and medical professionals interested in the latest developments in cell therapy, and particularly the application of CAR-T cell therapy in cancer treatment. Dive into this groundbreaking field with us, as we lead the path into the new era of cancer treatment.

Key Topics

Join us for a deep dive into cell immunotherapy in the context of CAR T-cell therapy for cancer treatment. This webinar will explore the background and evolution of CAR T cells, offering insights into the practical applications of CAR T-cell therapy through a series of case studies.

Our expert speaker will also discuss the current market presence of CAR T cells and the market potential for cell therapy research. You’ll gain a comprehensive overview of the products available to support your cell therapy research, including CAR vectors, cell lines and mouse models.

Topics Covered:
  • The Basics of cell therapy – Principles & market
  • Introduction of Cyagen’ s one-stop solution for cell therapy
  • Coverage of Cell therapy CRO services
  • Cell therapy products offered from Cyagen
Who should attend?
  • Oncologists and hematologists specializing in cancer treatment.
  • Researchers and scientists in the field of immunology and cell therapy.
  • Pharmaceutical and biotechnology professionals involved in cancer therapeutics.
  • Clinical trial investigators and coordinators.
  • Medical professionals seeking to enhance their knowledge of CAR-T cell therapy.
  • Healthcare professionals interested in the latest advancements in cancer treatment.
  • Patient advocates and support groups focused on cancer care.
  • Regulatory and policy professionals involved in evaluating and approving cell therapies.
  • Students and academics in the field of biomedical sciences and cancer research.
  • Investors and entrepreneurs interested in the development and commercialization of CAR-T cell therapies.
Attend this webinar to:
  • Discover the principles of cell therapy
  • Learn what the CAR T-cell therapy market looks like
  • Gain insights into cell therapy CRO services
  • Hear about the one-stop platform and cell therapy products offered by Cyagen
Mark Loetzerich, Ph.D.
Senior Scientific BD Manager

Mark Loetzerich earned his PhD in molecular virology from the Ludwig Maximilian University Munich in Germany. With almost 20 years of work experience, he is an expert in the fields of both RNA- and DNA viruses & immunology. In Switzerland, Mark specialized on virus-host interactions, cell death, and immune evasion mechanisms of respiratory viruses and possible countermeasures. In the USA, Mark led a highly translational research project at the Hussman Institute in Baltimore linked to viral triggers of multiple sclerosis. Prior to joining Cyagen, he worked as director for infectious disease for the gene therapy program of UPenn in Philadelphia on a new biologic platform for the treatment of COVID-19 and to transfer this technology to other pandemic viral threads. Mark obtained a post-baccalaureate certificate in biochemical regulatory engineering from the UMBC and was decorated with the Hussman Meritorious Award.

About Cyagen

Cyagen Biosciences is a 900-employee company headquartered in Santa Clara, California, with additional locations in Germany, Japan, and China. Cyagen offers a “one-stop shop” tailored to biomedical scientists’ gene research needs. Cyagen is the world's largest provider of custom-engineered mouse and rat models. Our custom murine model generation services range from DNA vector construction to embryonic stem cell manipulation, microinjection, breeding, and more. All projects are fully customizable and flexible. Cyagen provides comprehensive Contract Research Organization (CRO) services for cell and gene therapy (CGT) research, including viral vector development, CAR design and construction, disease models, phenotype analysis, and pharmacodynamic evaluations.

One-stop Service Platform for CAR-T Cell Therapy Research

Drawing on years of research experience in tumor immunology, Cyagen offers a full range of services to support research and development of CAR-T/-NK and other cell therapies, including antibody development, CAR molecular design, CAR lentivirus preparation, immune cell preparation and phenotype testing, cell and animal model construction, and in vitro/in vivo efficacy evaluation.

As part of our ongoing development of CRO service capabilities for CGT research, Cyagen has accumulated a wealth of CAR vector libraries and stable cell banks, and these libraries are still growing. Our goal is to provide customers with fast and convenient off-the-shelf products and accelerate research progress.

Check out the One-stop Service Platform for CAR-T Cell Therapy Research >>